Strong drug sales, Actelion buy power J&J's profit beat

(Reuters) - Johnson & Johnson reported a higher-than-expected quarterly profit and raised its full-year forecast, driven by strong demand for its new cancer drugs and gains from its acquisition of Swiss biotech Actelion.

Strong drug sales, Actelion buy power J&J's profit beat
Read More


Bagikan Berita Ini